Aerska, a biotechnology company developing brain shuttle technology to deliver RNA medicines to the central nervous system, has closed a $39 million Series A financing led by EQT Dementia Fund and age1, with participation from Iaso Ventures and continued support from existing investors.
The company said the new capital will be used to advance its antibody oligo conjugate (AOC) platform designed to improve delivery of RNA interference (RNAi) therapeutics across the blood-brain barrier, a long-standing hurdle for treating neurological diseases with RNA-based approaches.
Aerska said the round brings its total funding to $60 million since launch, following a seed funding announcement in October 2025. The company plans to continue developing its AOC platform as it progresses toward clinical-stage work focused on systemically delivered RNAi therapeutics for neurological disease targets.
Aerska’s platform aims to enable RNA medicines that can reach the brain after intravenous or subcutaneous administration, with the goal of achieving broad brain distribution and durable target gene knockdown. The company is initially focused on genetically driven forms of Alzheimer’s disease and other neurological disorders.
As part of the financing, Aerska added three new members to its board: Arno de Wilde, Managing Director at EQT; Philip Scheltens, Partner and Head of the Dementia Fund at EQT Life Sciences; and Alex Colville, General Partner at age1.
Aerska is headquartered in Dublin, Ireland, with research operations in London, UK.
KEY QUOTES
“The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration. Partnering with EQT Dementia Fund further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically-driven forms of Alzheimer’s disease and other devastating brain disorders.”
Jack O’Meara, Chief Executive Officer and Co-Founder, Aerska
“For families facing diseases like Alzheimer’s, Aerska’s approach offers hope for preserving cognitive function and quality of life. The team’s strategy of upstream intervention, combined with a focus on the genetic forms of neurological disease, positions them to transform outcomes for populations who have been underserved by current therapeutic approaches. We really look forward to working with this talented team to advance this groundbreaking platform.”
Philip Scheltens, Partner and Head of The Dementia Fund, EQT Life Sciences
